Skip to main content

Advertisement

Table 1 Counts of product labels and all linked claims

From: Dynamic enhancement of drug product labels to support drug safety, efficacy, and effectiveness

Drug Number of product labels Number of VANDFRT Number of DIKB inhibits/substrate ClinicalTrials.gov Published results
  for products containing DDIs found for of assertions with evidence studies involving the from ClinicalTrials.gov
  the drug the drug found for the drug drug studies involving the drug
   Significant Critical Evidence for Evidence against   
Antidepressants        
Amitriptyline 57 16 8 0 0 1 1
Amoxapine 2 15 8 0 0 0 0
Bupropion 111 7 4 2 0 5 44
Citalopram 85 25 9 2* 4* 4 25
Desipramine 15 16 10 0 0 0 0
Doxepin 32 15 9 0 0 0 0
Duloxetine 17 26 8 3 4 4 4
Escitalopram 20 13 3 4* 5* 6 9
Fluoxetine 90 51 14 2 0 8 22
Imipramine 19 18 10 0 0 1 4
Mirtazapine 55 2 5 4 9 1 22
Nefazodone 5 39 20 3 6 0 0
Nortriptyline 29 16 11 0 0 3 24
Paroxetine 60 33 11 2 0 3 40
Selegiline 11 2 47 0 0 1 1
Sertraline 74 28 8 2 0 3 27
Tranylcypromine 2 3 61 0 0 3 71
Trazodone 38 8 10 1 0 2 2
Trimipramine 2 17 10 0 0 0 0
Venlafaxine 66 21 6 3 3 2 2
Antipsychotics        
Aripiprazole 15 4 0 2 13 3 3
Clozapine 9 29 2 3 1 3 9
Olanzapine 42 0 1 1 0 5 13
Quetiapine 33 8 0 1 9 4 9
Risperidone 71 13 0 2 1 23 70
Ziprasidone 22 54 23 2* 9* 1 6
Sedative Hypnotics        
Eszopiclone 11 7 0 1 7 1 1
Zaleplon 24 0 0 1 1 0 0
Zolpidem 85 0 0 2 0 0 0
  1. *Citalopram, escitalopram, and ziprasidone were each mapped to one claim for which there was both supporting and refuting evidence in the DIKB. Counts of product labels for each drug and claims that were linked to drug product labeling from three Linked Data drug information sources.